US biotech company Alios BioPharma has secured $8 million (£5 million) from SR One, GlaxoSmithKline’s venture arm.

US biotech company Alios BioPharma has secured $8 million (£5 million) from SR One, GlaxoSmithKline’s venture arm.

This completes Alios’s Series A funding round, in which it has raised a total of $32 million. The first closing was in December, led by Switzerland-based Novartis Venture Fund and Denmark-headquartered Novo with participation from the investment arm of global healthcare group Roche.

As part of SR One’s investment, partner Kent Gossett will join Alios’s board, which also accommodates members of Novartis, Novo and Roche Venture Fund.

California-based Alios is developing medicines to treat disease through the immune system.